StockData
Repligen Corp logo

Repligen Corp (RGEN) stock

RGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 7/30132% above fair value
$172.67+10.49 (+6.47%)

Close on Nov 18, 2026Market cap $11.04BP/E –Yield –

Repligen operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Repligen's operating income for the twelve months ending Sep 30, 2026 was $18.24M, up 2185.5% year over year. For fiscal 2025 it was $55.17M. Over ten years it grew 14.9% a year on average. The highest annual figure on record is $224.67M in fiscal 2022.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$55.17M–
FY2024Dec 31, 2024-$35.11M-173.6%
FY2023Dec 31, 2023$47.70M-78.8%
FY2022Dec 31, 2022$224.67M+34.3%
FY2021Dec 31, 2021$167.25M+139.5%
FY2020Dec 31, 2020$69.82M+93.5%
FY2019Dec 31, 2019$36.08M+38.8%
FY2018Dec 31, 2018$25.99M+85.6%
FY2017Dec 31, 2017$14.01M-12.3%
FY2016Dec 31, 2016$15.97M+16.1%
FY2015Dec 31, 2015$13.76M+28.7%
FY2014Dec 31, 2014$10.69M-53.3%
FY2013Dec 31, 2013$22.87M–
FY2011Mar 31, 2011-$374.07K–
FY2010Mar 31, 2010-$5.77M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$29.55M-275.6%
Q2 FY2026Jun 30, 2026$13.98M+0.6%
Q1 FY2026Mar 31, 2026$15.94M+142.3%
Q4 FY2025Dec 31, 2025$17.87M–
Q3 FY2025Sep 30, 2025$16.83M–
Q2 FY2025Jun 30, 2025$13.90M+154.1%
Q1 FY2025Mar 31, 2025$6.58M+75.4%
Q4 FY2024Dec 31, 2024-$36.50M-469.7%
Q3 FY2024Sep 30, 2024-$7.83M-267.0%
Q2 FY2024Jun 30, 2024$5.47M-71.6%
Q1 FY2024Mar 31, 2024$3.75M-72.9%
Q4 FY2023Dec 31, 2023$9.87M-79.8%
Q3 FY2023Sep 30, 2023$4.69M-91.1%
Q2 FY2023Jun 30, 2023$19.28M-69.5%
Q1 FY2023Mar 31, 2023$13.86M-76.9%
Q4 FY2022Dec 31, 2022$48.84M+30.5%
Q3 FY2022Sep 30, 2022$52.67M+16.5%
Q2 FY2022Jun 30, 2022$63.17M+30.9%
Q1 FY2022Mar 31, 2022$60.00M+64.9%
Q4 FY2021Dec 31, 2021$37.43M+114.9%
Q3 FY2021Sep 30, 2021$45.19M+115.6%
Q2 FY2021Jun 30, 2021$48.24M+146.9%
Q1 FY2021Mar 31, 2021$36.38M+205.6%
Q4 FY2020Dec 31, 2020$17.42M+195.5%
Q3 FY2020Sep 30, 2020$20.96M+163.2%
Q2 FY2020Jun 30, 2020$19.54M+76.7%
Q1 FY2020Mar 31, 2020$11.91M+6.6%
Q4 FY2019Dec 31, 2019$5.89M-24.9%
Q3 FY2019Sep 30, 2019$7.96M+1.0%
Q2 FY2019Jun 30, 2019$11.05M+158.7%
Q1 FY2019Mar 31, 2019$11.17M+86.9%
Q4 FY2018Dec 31, 2018$7.85M+140.7%
Q3 FY2018Sep 30, 2018$7.89M–
Q2 FY2018Jun 30, 2018$4.27M-21.9%
Q1 FY2018Mar 31, 2018$5.98M+5.3%
Q4 FY2017Dec 31, 2017$3.26M+12.3%
Q3 FY2017Sep 30, 2017-$406.00K–
Q2 FY2017Jun 30, 2017$5.47M–
Q1 FY2017Mar 31, 2017$5.68M–
Q4 FY2016Dec 31, 2016$2.91M–

More Repligen figures

See a number that looks wrong?